Excellent Response to OnabotulinumtoxinA: Different Definitions, Different Predictors

The identification of patients who can benefit the most from the available preventive treatments is important in chronic migraine. We explored the rate of excellent responders to onabotulinumtoxinA in a multicenter European study and explored the predictors of such response, according to different d...

Ausführliche Beschreibung

Bibliographische Detailangaben

Veröffentlicht in:	International journal of environmental research and public health 2022-09, Vol.19 (17), p.10975
Hauptverfasser:	Ornello, Raffaele, Baraldi, Carlo, Ahmed, Fayyaz, Negro, Andrea, Miscio, Anna Maria, Santoro, Antonio, Alpuente, Alicia, Russo, Antonio, Silvestro, Marcello, Cevoli, Sabina, Brunelli, Nicoletta, Vernieri, Fabrizio, Grazzi, Licia, Pani, Luca, Andreou, Anna, Lambru, Giorgio, Frattale, Ilaria, Kamm, Katharina, Ruscheweyh, Ruth, Russo, Marco, Torelli, Paola, Filatova, Elena, Latysheva, Nina, Gryglas-Dworak, Anna, Straburzyński, Marcin, Butera, Calogera, Colombo, Bruno, Filippi, Massimo, Pozo-Rosich, Patricia, Martelletti, Paolo, Guerzoni, Simona, Sacco, Simona
Format:	Artikel
Sprache:	eng
Schlagworte:	Botulinum toxin type A Botulinum Toxins, Type A - therapeutic use Chronic Disease Female Headache Headaches Humans Migraine Migraine Disorders - drug therapy Monoclonal antibodies Patients Treatment Outcome
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!